CYSVIEW® BLUE-LIGHT
CYSTOSCOPY (BLC™)
Cysview® (hexaminolevulinate hydrochloride) is indicated as an adjunct to white-light cystoscopy in the detection of non-muscle invasive papillary bladder cancer, in patients with known or suspicion of bladder cancer.
Click here for Part III: Consumer Information of the Product Monograph
Ask your doctor or hospital about new tools to help detect
non-muscle invasive papillary bladder cancer. Ask your doctor if you are a suitable patient.

Hospitals Using Cysview®
- Brockville General Hospital (Brockville, ON)
- Humber River Hospital (Toronto, ON)
- Kingston General Hospital (Kingston, ON)
- Vancouver General Hospital (Vancouver, BC)
- University of British Columbia (Vancouver, BC)
- Surrey Memorial Hospital (Surrey, BC)
- Jim Pattison Outpatient Care and Surgery Centre (Surrey, BC)
- Toronto General Hospital (Toronto, ON)
- Health Sciences North (Sudbury, ON)
- Centre universitaire de sante McGill (CUSM) - Glen Site (Montreal, QC)
- Jewish General Hospital (Montreal, QC)
- Ridge Meadows Hospital (Maple Ridge, BC)
Check this page regularly for updates
Hospitals in the Process of Evaluating/Considering Cysview®
- Victoria General Hospital (Victoria, BC)
- Kelowna General Hospital (Kelowna, BC)
- University of Alberta (Edmonton, AB)
- London Health Sciences Centre (London, ON)
In The News
March 14, 2019 - As seen in MacLean's Magazine - Personal Health News
March 14, 2019 - As seen in MacLean's Magazine - Personal Health News
Jan 10, 2019 - Sachem.ca
Dec 22, 2018 - As seen in the Toronto Star - Personal Health News
Nov 9, 2018 - As seen in MacLean's Magazine - Personal Health News
Jun 1, 2018 - Vancouver Sun
Mar 15, 2018 - PersonalHealthNews.ca
Jan 25, 2018 - TorontoSun.com
Nov 20, 2017 - UNC.org
April 5, 2017 - TheWhig.com
March 24, 2017 - KGH Connect
Jan 20, 2017 - InsideToronto.com